Skip to main content
SpringerLink
Log in

Rosiglitazone: new restrictions in Canada

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Reblin T.AVANDIA, AVANDAMET and AVANDARYL - Important new restrictions on the use of rosiglitazone products due to information on cardiovascular related events - for health professionals. Internet Document: [5 pages], 9 Nov 2010. Available from: URL: http://www.hc-sc.ga.ca

  2. Reblin T.AVANDIA, AVANDAMET and AVANDARYL - Important new restrictions on the use of rosiglitazone products due to information on heart-related events - for the public. Internet Document: [4 pages], 18 Nov 2010. Available from: URL: http://www.hc-sc.ga.ca

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosiglitazone: new restrictions in Canada. React. Wkly. 1329, 4 (2010). https://doi.org/10.2165/00128415-201013290-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201013290-00007

Keywords

Search

Navigation